A Double-blind, Placebo-controlled, Randomized, Multicenter Phase-II Trial to Assess the Efficacy of Sorafenib Added to Standard Primary Therapy in Patients With Newly Diagnosed AML ≤60 Years of Age
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Event-free survival
36 months
Yes
Gerhard Ehninger, Prof, MD
Principal Investigator
University Hospital Dresden
Germany: Federal Institute for Drugs and Medical Devices
TUD-SORAML-034
NCT00893373
March 2009
Name | Location |
---|